Board Certification and Academic Information
||Pediatrics - Professor (Clinical)
||American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Ped Hematology-Oncology)
Academic Office Locations
|Academic Office Phone Number
||Academic Office Address
||Primary Children's Hospital
100 N Mario Capecchi Drive
Salt Lake City, UT 84113
Hassan M Yaish, MD.
Graduated from college of Medicine, University of Damascus in 1964
Internship in internal medicine and pediatrics at Augesta Victoria Hospital in Jerusalem and Damascus city Hospital in Damascus, Syria.
Residency in pediatrics at the Royal medical services at the base hospital in Amman, Jordan and William Beaumont hospital in Royal Oak, Michigan
Hematology /Oncology fellowship at william Beaumont hospital, Royal Oak , MI.
Studies conducted during fellowship were mostly on thrombocytopenia in children resulting in an original publication in journal of pediatrics in 1975 confirming , for the first time , the efficacy of steroids therapy in children with ITP, contrary to what was believed by others at that time.
Intense training in blood cells morphology and technical procedures to assist in the diagnosis of blood disorders especially in the neonates and infants.
1984-1992 served as chairman of the department of pediatrics at a tertiary care medical center in Riyadh , Saudi Arabia ( King Fahad Hospital and medical center) where I established the first pediatric oncology department . I served as assistant then associate professor of pediatrics at King Saud university in Riyadh.
During that period, I encountered several clinical pictures in infants and young children ranging from slight anemia and learning disability to severe encephalopathy of unknown etiology which were later on proved to be related to lead poisoning . The clue was the basophilic stippling i noted on blood smear examination. I conducted some research and established a public campain to raise awareness for prevention and early identification of affected children.
I also started a program to screen newborns for Red Blood Cells abnormalities including hemoglobinopathies and enzymopathies. Several publications on the topics were published in local and international journals.
I served as division head of pediatric hematology at Henry Ford Hospital in Detroit ,MI from 1992 -2002. During that period I ran a service taking care of patients with lead poisoning , sickle cell disease and Thalassemia. I was mentoring and teaching students from university of Michigan as well as from Case western university, where I held an assistant professor title at the second.
2003 - Present. I joined the Primary children Medical Center, and the University of Utah as a pediatric hematologist oncologist.
I was initially appointed as associate professor before being promoted to professor. My main contribution to the program was the introduction of microscopic morphology as a major tool for diagnosing blood disorers rather that depending on extensive battery of costly tests to reach a diagnosis. Training many fellows and residents as well as medical students in morphology , has changed the culture in the institution . Morphology became a valuable tool in patient care and management.
I coordinate the monthly hematopathology tumor board meeting discussing the very unusual and morphologically challenging cases in the form of teaching session for large group of trainees and attendings.
During the last few years, many students, house officers and fellows became skilled in the field of morphology and were able to teach and instruct their juniors resulting in extending the life of the field of morphology, which many thought and feared that it will soon die away.
Several papers on morphologic diagnoses were published. Last year an application for a grant to help identifying the cause of extreme hyperbilirubinemia in neonates was submitted and a neonatal hematology clinic was established. It is hoped that many of the more than 50% idiopathic hyperbilirubinemia in neonates will not be idiopathic any more if one will be able to examine each blood smear of such babies.
I have participated in Several national research studies some are currently ongoing : The CDC study of inhibitors to clotting factors in patients with Hemophilia, the utilization of Thrombopoietin agonists for treatment of chronic refractory ITP, as well as trials for the efficacy and safety of new clotting factors in patients with hemophilia.